ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för LCL161. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

26 träffar

Bibliografisk träff 2023-07-31

Molecular basis for nuclear accumulation and targeting of the inhibitor of apoptosis BIRC2.

Tencer AH, Yu Y, Causse SZ, Campbell GR, Klein BJ, Xuan H, Cartier J, Miles MA, Gaurav N, Zadoroznyj A, Holt TA, Wen H, Hawkins CJ, Spector SA, Dubrez L, Shi X, Kutateladze TG.

Nat Struct Mol Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41594-023-01044-1

Bibliografisk träff 2023-07-10

Natural Flavonoids Quercetin and Kaempferol Targeting G2/M Cell Cycle-Related Genes and Synergize with Smac Mimetic LCL-161 to Induce Necroptosis in Cholangiocarcinoma Cells.

Lomphithak T, Jaikla P, Sae-Fung A, Sonkaew S, Jitkaew S.

Nutrients · research-article; journal article · DOI 10.3390/nu15143090

Bibliografisk träff 2023-07-01

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.

Johnson ML, Patel MR, Aljumaily R, Jones SF, Burris Iii HA, Spigel DR.

Oncologist · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/oncolo/oyad029

Bibliografisk träff 2023-04-17

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.

Afsahi A, Silvestri CM, Moore AE, Graham CF, Bacchiochi K, St-Jean M, Baker CL, Korneluk RG, Beug ST, LaCasse EC, Bramson JL.

Front Immunol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fimmu.2023.1179827

Bibliografisk träff 2023-01-06

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.

Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S.

Front Oncol · published erratum; correction · DOI 10.3389/fonc.2022.1124912

Bibliografisk träff 2022-11-30

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.

Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2022.1021632

Bibliografisk träff 2022-10-11

Induction of Breast Cancer Cell Apoptosis by TRAIL and Smac Mimetics: Involvement of RIP1 and cFLIP.

Holmgren C, Sunström Thörnberg E, Granqvist V, Larsson C.

Curr Issues Mol Biol · research-article; journal article · DOI 10.3390/cimb44100327

Bibliografisk träff 2022-01-30

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.

Morita S, Minami H, Mitsuma A, Toyoda M, Kiyota N, Ando Y.

Asia Pac J Clin Oncol · clinical trial, phase i; journal article · DOI 10.1111/ajco.13744

Bibliografisk träff 2022-01-07

The combination of TRAIL and the Smac mimetic LCL-161 induces an irreversible phenotypic change of MCF-7 breast cancer cells.

Granqvist V, Holmgren C, Larsson C.

Exp Mol Pathol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yexmp.2021.104739

Bibliografisk träff 2021-09-08

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-021-03062-3

Bibliografisk träff 2021-08-16

The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.

Harris MA, Shekhar TM, Miles MA, Cerra C, Hawkins CJ.

Clin Exp Metastasis · research support, non-u.s. gov't; journal article · DOI 10.1007/s10585-021-10116-9

Bibliografisk träff 2021-08-01

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S.

Blood Adv · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2020003829

Bibliografisk träff 2020-06-01

The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells.

Chang YC, Kondapuram SK, Yang TH, Syed SB, Cheng SM, Lin TY, Lin YC, Coumar MS, Chang JY, Leung E, Cheung CHA.

Toxicol Appl Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.taap.2020.115080

Bibliografisk träff 2020-01-02

The SMAC mimetic LCL-161 selectively targets JAK2<sup>V617F</sup> mutant cells.

Craver BM, Nguyen TK, Nguyen J, Nguyen H, Huynh C, Morse SJ, Fleischman AG.

Exp Hematol Oncol · research-article; journal article · DOI 10.1186/s40164-019-0157-6

Bibliografisk träff 2019-09-14

Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.

Shekhar TM, Burvenich IJG, Harris MA, Rigopoulos A, Zanker D, Spurling A, Parker BS, Walkley CR, Scott AM, Hawkins CJ.

BMC Cancer · research-article; journal article · DOI 10.1186/s12885-019-6103-5

Bibliografisk träff 2019-06-01

Induction of Necroptosis in Human Breast Cancer Drug-Resistant Cells by SMAC Analog LCL161 After Caspase Inhibition Requires RIP3.

Jin G, Liu Y, Xu P, Jin G.

Pharmazie · research support, non-u.s. gov't; journal article · DOI 10.1691/ph.2019.9307

Bibliografisk träff 2019-04-23

LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.

Yang L, Kumar B, Shen C, Zhao S, Blakaj D, Li T, Romito M, Teknos TN, Williams TM.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-18-1157

Bibliografisk träff 2018-12-01

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.

Runckel K, Barth MJ, Mavis C, Gu JJ, Hernandez-Ilizaliturri FJ.

Blood Adv · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2018018168

Bibliografisk träff 2018-09-20

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol · journal article · DOI 10.1200/jco.2017.74.8392

Bibliografisk träff 2018-01-31

Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.

Frommann K, Appl B, Hundsdoerfer P, Reinshagen K, Eschenburg G.

J Pediatr Surg · journal article · DOI 10.1016/j.jpedsurg.2018.01.012

Bibliografisk träff 2016-09-30

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.

Yang C, Wang H, Zhang B, Chen Y, Zhang Y, Sun X, Xiao G, Nan K, Ren H, Qin S.

J Exp Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13046-016-0435-7

Bibliografisk träff 2016-09-01

[Effects of LCL161, a Smac mimetic on the proliferation and apoptosis in hepatocellular carcinoma cells].

Ren K, Ma L, Chong D, Zhang Z, Zhou C, Liu H, Zhao S.

Zhong Nan Da Xue Xue Bao Yi Xue Ban · journal article · DOI 10.11817/j.issn.1672-7347.2016.09.003

Bibliografisk träff 2016-04-04

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.

West AC, Martin BP, Andrews DA, Hogg SJ, Banerjee A, Grigoriadis G, Johnstone RW, Shortt J.

Oncogenesis · letter; journal article · DOI 10.1038/oncsis.2016.26

Bibliografisk träff 2016-02-04

Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.

Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kübler AC, Müller-Richter UDA.

Clin Oral Investig · journal article · DOI 10.1007/s00784-016-1741-3

Bibliografisk träff 2014-06-27

Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.

Tian A, Wilson GS, Lie S, Wu G, Hu Z, Hebbard L, Duan W, George J, Qiao L.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2014.06.006

Bibliografisk träff 2012-05-09

Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.

Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2012.04.023